Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2233–2256 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Psoriatic Arthritis
Interventions: Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more

Conditions: Obesity
Interventions: CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 15
States / cities: Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more

Conditions: Carbon Monoxide Poisoning
Interventions: Hyperbaric Oxygen (HBO2) - 3 sessions, Hyperbaric Oxygen (HBO2) - 1 session; Combination Product
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years to 79 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Diabetes Mellitus, Type 2
Interventions: CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miramar, Florida • San Antonio, Texas • Tacoma, Washington

Conditions: Pain, Postoperative Pain, Pain, Acute
Interventions: MR-107A-01, Placebo; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Smoking Cessation
Interventions: X-22 Smoking Cessation Product, Active Control Cigarettes; Drug
Lead sponsor: 22nd Century Limited, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Sacramento, California • Metairie, Louisiana • Austin, Texas

Conditions: Diarrhea, Malaria
Interventions: Zinc sulphate, Placebo; Dietary Supplement · Other
Lead sponsor: United States Army Research Institute of Environmental Medicine; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Natick, Massachusetts • Grand Forks, North Dakota

Conditions: Clostridium Difficile
Interventions: Serum-derived bovine immunoglobulin/protein isolate (SBI), Placebo; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois

Conditions: Asthma
Interventions: Pictorial Asthma Action Plan, Written Asthma Action Plan; Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 8 Years to 17 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions: Insulin, Placebo (Sterile diluent); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease
Interventions: Standard of care + Mediterranean diet (intervention), Standard of care (control); Other
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 85 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Health Behavior
Interventions: MaaS app, No app; Other
Lead sponsor: Florida Atlantic University; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Colorectal Cancer (CRC)
Interventions: Sotorasib, Panitumumab, Trifluridine and Tipiracil, Regorafenib; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 16 more

Conditions: Parkinson Disease, Fatigue, Parkinsonism
Interventions: Northera, Placebo Oral Tablet; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Acne Vulgaris
Interventions: 1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient); Combination Product
Lead sponsor: Biofrontera Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 9
States / cities: Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more

Conditions: Hysterectomy
Interventions: Chlorhexidine, Iodine; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight, Type 2 Diabetes
Interventions: Lorcaserin hydrochloride, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 14,673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 373
States / cities: Alexander City, Alabama • Athens, Alabama • Birmingham, Alabama + 283 more

Conditions: Restless Leg Syndrome
Interventions: BRC-002, Placecbo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: EUS Guided Biopsy
Interventions: Fork-tip Needle, Franseen Needle; Device
Lead sponsor: Henning Gerke; Other
Eligibility: 18 Years to 85 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Ulcerative Colitis
Interventions: Basiliximab; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 25
States / cities: Anaheim, California • Roseville, California • Golden, Colorado + 22 more

Conditions: Viruria
Interventions: Placebo, Brincidofovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 15
States / cities: San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 10 more

Conditions: Refractory Chronic Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 55
States / cities: Peoria, Arizona • Little Rock, Arkansas • Los Angeles, California + 51 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide 15mg, Lenalidomide 25mg; Drug
Lead sponsor: Boston VA Research Institute, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: Little Rock, Arkansas • Los Angeles, California • Hines, Illinois + 4 more

Conditions: Pain, Postoperative, Root Canal Infection, Endodontically Treated Teeth
Interventions: GentleWave, Conventional Protocol; Other
Lead sponsor: University of Salamanca; Other
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Manhattan, New York

Search by objective public record fields.

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

Dose-Response Study of MR-107A-01 in The Treatment of Post-Surgical Dental Pain

Randomized Trial to Evaluate the Effectiveness of X-22 as a Smoking Cessation Aid

Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.

To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients

Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

Evaluating a Travel App's Influence on College Student Commuting to Campus

Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

Vaginal Preparation Prior to Hysterectomy

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Tolerability and Efficacy of CBD Extract for RLS Treatment

SharkCore Versus Acquire FNB

Basiliximab in Moderate to Severe Ulcerative Colitis

CMX001 in Post-transplant Patients With BK Virus Viruria

Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Effectiveness of GentleWave System in Endodontic Treatment